Uric acid as a link between renal dysfunction and both pro-inflammatory and prothrombotic state in patients with metabolic syndrome and coronary artery disease

Kardiologia Polska

Volumn 69, Issue 4, 2011, Pages 319-326

  Zapolski, Tomasz ^a   Waciński, Piotr ^a   Kondracki, Bartosz ^a   Rychta, Elzbieta ^a   Buraczyńska, Monika J ^a   Wysokiński, Andrzej ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Diabetes mellitus; Inflammation; Metabolic syndrome; Prothrombotic state; Uric acid

Indexed keywords

AMINOTRANSFERASE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHOLESTEROL; FIBRINOGEN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; URIC ACID;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROSCLEROSIS; BLOOD CELL COUNT; BODY HEIGHT; BODY MASS; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DIABETIC PATIENT; DISEASE ASSOCIATION; FAMILY HISTORY; FEMALE; FIBRINOGEN BLOOD LEVEL; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INFLAMMATION; ISCHEMIC HEART DISEASE; KIDNEY DYSFUNCTION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; RISK FACTOR; SMOKING; THROMBOSIS; TRIACYLGLYCEROL BLOOD LEVEL; UREA BLOOD LEVEL; WAIST CIRCUMFERENCE; WAIST HIP RATIO;

EID: 79955377535     PISSN: 00229032     EISSN: 00229032     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Hsu CY, McCulloch CE, Iribarren C et al. Body mass index and risk for end-stage renal disease. Ann Intern Med, 2006; 144: 21-28. (Pubitemid 46780716)
2. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risk of death, cardiovascular events, and hospitalization. N Engl J Med, 2004; 351: 1296-1305.
3. Yilmaz H, Sayar N, Yilmaz M et al. Serum paraoxonase 1 activity in women with metabolic syndrome. Kardiol Pol, 2010; 68: 1219-1224.
4. Kayaa EB, Yorguna H, Canpolata U et al. Serum uric acid levels predict the severity and morphology of coronary atherosclerosis detected by multidetector computed tomography. Atherosclerosis, 2010; 213: 178-183.
5. Lee J, Sparrow D, Vokonas S, Landsberg L. Uric acid and coronary heart disease risk: evidence for a role of uric acid in the obesity-insulin resistance syndrome. Am J Epidemiol, 1995; 142: 3-8.
6. Weiner DE, Tighiouart H, Elsayed EF et al. Uric acid and incident kidney disease in the community. J Am Soc Nephrol, 2008; 19: 1204-1211.
7. Haffner SM. The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. Am J Cardiol, 2006; 97: 3A-11A.
8. Odrowa̧ż-Sypniewska G. Markers of pro-inflammatory and pro-thrombotic state in the diagnosis of metabolic syndrome. Adv Med Scien, 2007; 52: 246-250.
9. Levey AS, Bosh JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine. A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med, 1999; 130: 461-470.
10. Fox CS, Larson MG, Leip EP et al. Predictors of new-onset kidney disease in a community-based population. JAMA, 2004; 291: 844-850. (Pubitemid 38543772)
11. Ejerbald E, Fored CM, Lindblad P et al. Obesity and risk for chronic renal failure. J Am Soc Nephrol, 2006; 17: 1695-1702. (Pubitemid 43794672)
12. Stengel B, Tarver-Carr ME, Powe NR et al. Lifestyle factors, obesity and the risk of chronic kidney disease. Epidemiology, 2003; 14: 479-487. (Pubitemid 40417067)
13. Pinto-Sietsma SJ, Navis G, Jansen WM et al. A central body fat distribution is related to renal function impairment, even in lean subjects. Am J Kidney Dis, 2003; 41: 733-741. (Pubitemid 36401550)
14. Vijayan A, Franklin SC, Behrend T et al. Insulin-like growth factor I improves renal function in patients with end-stage chronic renal failure. Am J Physiol, 1999; 276: R929-R934. (Pubitemid 29214161)
15. Morales E, Valero MA, Leon M et al. Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis, 2003; 41: 319-327. (Pubitemid 36152449)
16. Muntner P, Coresh J, Smith JC et al. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int, 2000; 58: 1908-1919.
17. Esposito K, Pontillo A, Di Palo C et al. Effect of weight loss and lifestyle changes on vascular inflammatory makers in obese women: a randomised trial. JAMA, 2003; 289: 1799-1804. (Pubitemid 37430249)
18. Tchernof P, Nolan A, Sites CK et al. Weight loss reduces C-reactive protein levels in obese postmenopausal women. Circulation, 2002; 105: 564-569. (Pubitemid 34123429)
19. Bisoendial RJ, Boekholdt SM, Vergeer1 M et al. C-reactive protein is a mediator of cardiovascular disease. Eur Heart J, 2009; 31: 2087-2091.
20. Nakagawa T, Kang DH, Feig D et al. Unearthing uric acid: An ancient factor with recently found significance in renal and cardiovascular disease. Kidney Int, 2006; 69: 1722-1725. (Pubitemid 43739197)
21. Lin S-D, Tsai D-H, Hsu S-R. Association between serum uric acid level and components of the metabolic syndrome. J Chin Med Assoc, 2006; 69: 512-516. (Pubitemid 46017171)
22. Nakagawa T, Hu H, Zharikov S et al. A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol, 2006; 290: F625-F631. (Pubitemid 43724964)
23. Faccini F, Chen YD, Hollenbeck CB et al. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA, 1999; 266: 3008-3011.
24. Iseki K, Ikemiya Y, Inoue T et al. Significance of hyperuricemia as a risk factor for developing ERDS in a screened cohort. Am J Kidney Dis, 2004; 44: 642-650. (Pubitemid 39237608)
25. Goicoechea M, García de Vinuesa S, Verdalles U et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol, 2010; 5: 1388-1393.
26. Ridker PM, Rifai N, Rose L et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular event. N Engl J Med, 2002; 347: 1557-1565. (Pubitemid 35315836)
27. Calabro P, Willerson JT, Eh ET. Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation, 2003; 108: 1930-1932. (Pubitemid 37296536)
28. Ruggiero C, Cherubini A, Ble A et al. Uric acid and inflammatory markers. Eur Heart J, 2006; 27: 1174-1181.
29. Kang DH, Park SK, Lee IK et al. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol, 2005; 16: 3553-3562.
30. Hayden MR, Tyagi SC. Uric acid: a new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: the urate redox shuttle. Nutrition Metabolism, 2004; 1: 1-15.
31. Kannelis J, Watanabe S, Li JH et al. Uric acid stimulates MCP-1 production in vascular smooth muscle cells via MAPK and COX-2. Hypertension, 2003; 41: 1287-1293.
32. Devaraj S, Xu DY, Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells. Implication for the metabolic syndrome and atherothrombosis. Circulation, 2003; 107: 398-404.